Evident partners with MedCurrent to meet CMS regulations and improve care quality

April 28, 2020

MOBILE, Ala. - Evident, a member of the CPSI (NASDAQ: CPSI) family of companies and a leading provider of electronic health record (EHR) systems and services, and MedCurrent, a physician‑founded Clinical Decision Support (CDS) company, today announced a partnership to help meet the regulatory requirements put into effect January 1, 2020, through the Protecting Access To Medicare Act (PAMA).

Under PAMA, in order to receive reimbursement for advanced diagnostic imaging exams starting January 1, 2021, including MRI and CT scans, a CMS-qualified Clinical Decision Support Mechanism (CDSM) must be used. With this partnership, MedCurrent will integrate its OrderWise® CDS offering with the Evident EHR using simple interoperability approaches and standards to help ensure reimbursement for various diagnostic exams that take place in the outpatient setting. This technology also enables care teams to administer the right test at the right time to enhance patient care.

Boyd Douglas, president and chief executive officer of CPSI, said, “In addition to fulfilling an important regulatory mandate, this partnership supports providers and other clinicians with real-time, evidence‑based guidelines at the point of care, leading to better outcomes and overall improved community health.”

Dr. Steve Herman, founder and chief executive officer of MedCurrent, said, “Our partnership with CPSI will provide seamless access to OrderWise directly within the Evident EHR workflows. CPSI is uniquely positioned as a leading provider of value-based solutions to healthcare providers. Through our partnership, we look forward to supporting their customers in continuing to drive optimization in healthcare delivery while addressing new CMS regulatory requirements.”

###About Evident

Evident, a member of the CPSI family of companies, recognizes the challenges hospitals, clinics and other healthcare providers face – the need for simplicity, cost containment and delivery of a quality healthcare experience for patients and physicians alike. Our integrated software solutions are backed by a proactive support approach, making us the partner of choice for hundreds of healthcare organizations. For more information, visit

###About MedCurrent

MedCurrent is a physician-founded Clinical Decision Support (CDS) company focused on improving the quality of care and managing health system costs through our innovative and scalable solution, OrderWise®. Our solution enhances the clinical decision-making process with real-time, evidence-based guidelines integrated at the point of care to improve health and healthcare delivery. Deep healthcare experience, superior technology and business agility make MedCurrent a global leader in CDS solutions. For more information, visit

###Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified generally by the use of forward-looking terminology and words such as “expects,” “anticipates,” “estimates,” “believes,” “projects,” “targets,” “predicts,” “intends,” “plans,” “potential,” “may,” “continue,” “should,” “will” and words of comparable meaning. Without limiting the generality of the preceding statement, all statements in this press release relating to Evident’s partnership with MedCurrent and the ability of the integrated product to help ensure reimbursement of hospital customers for various diagnostic exams are forward-looking statements. We caution investors that any such forward-looking statements are only predictions and are not guarantees of future performance. Certain risks, uncertainties and other factors may cause actual results to differ materially from those projected in the forward-looking statements. Such factors may include: risks related to Evident’s ability to successfully integrate its EHR software product with MedCurrent’s offering; whether the combined product offering will satisfy the requirements of CMS for reimbursement under PAMA; the continued spread of the COVID-19 global pandemic, including the speed, depth, geographic reach and duration of the spread, which could decrease demand for the Company’s products and services and adversely impact the operations and financial condition of our customers and the Company; actions to be taken by the Company in response to the pandemic; the legal, regulatory and administrative developments that occur at the federal, state and local levels; potential disruptions, breaches, or other incidents affecting the proper operation, availability, or security of the Company’s or its partners’ information systems, including unauthorized access to or theft of patient, business associate, or other sensitive information or inability to provide patient care because of system unavailability; changes in revenues due to declining hospital demand and deteriorating macroeconomic conditions (including increases in uninsured and underinsured patients); potential increased expenses related to labor or other expenditures; and the impact of our substantial indebtedness and the ability to refinance such indebtedness on acceptable terms or at all, as well as risks associated with disruptions in the financial markets and the business of financial institutions as the result of the COVID-19 pandemic which could impact us from a financial perspective. Numerous other risks, uncertainties and other factors may cause actual results to differ materially from those expressed in any forward-looking statements. Such factors include risk factors described from time to time in CPSI’s public releases and reports filed with the Securities and Exchange Commission, including but not limited to, CPSI’s most recent Annual Report on Form 10-K. We also caution investors that the forward-looking information described herein represents CPSI’s outlook only as of this date, and CPSI undertakes no obligation to update or revise any forward-looking statements to reflect events or development after the date of this press release.

Tracey Schroeder
Chief Marketing Officer
(612) 787-3125

Martin Kepa
Vice President, Account Management
(855) 279-3380 (ext. 424)